NY-GENESIS
27.1.2022 15:02:10 CET | Business Wire | Press release
Genesis , a digital asset industry pioneer and digital currency prime brokerage, today released its Q4 2021 Market Observations Report, which provides detail on the company’s growth over the past quarter and the whole year. This growth highlights major trends across institutional digital asset markets, including the continued diversification of digital asset investments, the deepening sophistication of institutional investors entering the crypto market, new types of institutions participating in the market, increasing allocations from managers of diversified portfolios and the growing need for multi-service institutional prime brokerages.
Q4 2021 marked Genesis’ strongest quarter to date, with approximately $102 billion in transactional volume, cementing a year of significant growth across all of its business lines. Highlights during the quarter across crypto lending, trading and custody include the following:
- Loan originations reached $50 billion, up 40% over Q3 2021. Loan originations for 2021 totaled $131 billion, nearly 7x higher than 2020.
- Spot trading volume totaled $30.8 billion, up 23% from Q3. For the full year 2021, Genesis’ spot trading volumes increased nearly 6x over 2020 to $116.5 billion.
- Derivatives notional volume traded was $20.7 billion during the quarter, an increase of 62% compared with Q3. Total notional value traded for the year grew to $53.8 billion, more than 9x over 2020.
- Onboarded Custody clients grew 53% from the previous quarter.
- Genesis’ headcount expanded 22% during the quarter to reach 170 employees, spread across three continents.
“2021 was a pivotal year for the crypto industry, and one that demonstrated the merits of smart tactical trading around a core position,” said Michael Moro, CEO of Genesis. “As this asset class continues to mature, driven by increasing institutional participation and growing regulatory clarity, we believe that taking a comprehensive approach to portfolio management will only become more important, and we look forward to achieving new milestones on behalf of our clients in 2022.”
Crypto Lending
Genesis’ lending desk remains the largest crypto lender in the industry and finished the year with over $150 billion in cumulative originations since its launch in March of 2018. Genesis executed a record $50 billion in new originations in Q4 alone, a 40% increase from the previous quarter, and marked the desk’s fifteenth consecutive quarter of growth. Active loans outstanding climbed to $12.5 billion to close the quarter, up 12.3% from Q3. Loans outstanding peaked at over $16 billion in mid-November before seeing a wave of year-end deleveraging as prices on most cryptocurrencies fell.
Over the quarter, the lending desk saw that while demand from clients engaging with DeFi platforms is still strong, focus has shifted towards layer-1 (L1) alternatives, resulting in slightly higher originations in those coins.
Derivatives and Spot Trading
Genesis saw another record quarter in derivatives trading activity with $20.7 billion in notional value traded globally, a 62% quarter-on-quarter growth and a 360% increase over Genesis’ results in Q4 2020. This brings trading activity for 2021 to $53.8 billion in notional volume, an 812% increase over 2020. In December, Genesis also printed the first ever ETH Micro futures trade on the CME and was #1 in market share for blocked BTC and ETH exchange-cleared options via Paradigm, with over $1.5 billion traded.
The Genesis spot desk traded $30.8 billion in volume in Q4, delivering the second-best quarter in the desk’s long history, as well as an increase of 23% over the prior quarter and a 279% increase over Q4 of 2020. Total spot trading volume for the year reached $116.5 billion, a 463% increase over 2020.
Custody
Genesis Custody closed 2021 with a 53% increase in the number of customers onboarded from Q3. The business also reached two critical milestones during Q4 一 Genesis Custody was approved by the Financial Conduct Authority (FCA) as a cryptoasset business, signifying its strong controls, governance and compliance frameworks to counter financial crime, and it completed the System and Organization Controls (SOC) 2 Type 1 examination.
Over the course of Q4, Genesis Custody also began staking assets for clients. The business has taken steps to continue to expand its portfolio of services offered, and to better integrate custody into its clients’ trading and portfolio management workflows.
The Genesis Q4 2021 Market Observations Report provides a comprehensive look into key market activity through insights from the firm’s spot trading, derivatives trading, lending, custody, treasury and prime brokerage businesses. To read the full Q4 2021 Market Observations Report, click here .
About Genesis
Genesis is a full-service digital currency prime brokerage providing a single point of access for select qualified individuals and global institutional investors. Genesis combines unrivaled operational excellence, a seamless user experience, and best-in-class client service to provide the full suite of services global investors require to manage their digital asset portfolios.
The firm offers sophisticated market participants a fully integrated platform to trade, borrow, lend, and custody digital assets, creating new opportunities for yield while increasing capital efficiency for counterparties.
Genesis is a wholly owned subsidiary of Digital Currency Group (DCG) , one of the largest private investors in blockchain and digital asset companies.
For more information on Genesis, please visit genesistrading.com and follow @GenesisTrading on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005286/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
